Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Amgen

    • Most Recent Events

    • 26 Apr 2022 Results of a pooled analysis of the double-blind treatment phases and open-label extension phases (NCT03096834, NCT01952574) assessed the long term safety presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 20 Dec 2021 Results of post-hoc secondary analysis of NCT01952574, NCT02456740, NCT02483585, NCT02066415, and NCT02174861 assessing the efficacy and safety profiles of erenumab in patients with migraine with aura, published in the JAMA Neurology.
    • 30 Sep 2021 Results of a pooled analysis assessing the risk of hypertension in patients with migraine who received Erenumab in clinical trials (NCT02066415 and NCT01952574) and two Phase 3 (NCT02456740 and NCT02483585) and in the postmarketing setting published in the Headache

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top